Our journals offer ESMO members and the oncology community a globally visible platform to publish scientific studies, and a highly credible source of educational updates.
There are many good reasons to become an ESMO member. Find out why you should join Europe's leading medical oncology society
An exciting, intensive course designed for the future leaders in our profession and our society. Apply by 7 January 2019!
The ESMO-MCBS scale is a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Dr. Marco Merlano comments on the findings from the KEYNOTE-048 trial and an academic trial comparing bio-radiotherapy with chemo-radiotherapy in oropharyngeal cancer presented at ESMO 2018 Congress.
13 Dec 2018
Similar response rates and survival were demonstrated with chemotherapy and immunotherapy in patients with advanced SCLC
13 Dec 2018
First line immunotherapy with durvalumab or the combination of durvalumab and tremelimumab does not improve overall survival in unselected patients...
12 Dec 2018
Most of the studies included in the analysis were published in influential journals
11 Dec 2018
New technologies in immuno-oncology that are set to benefit many more patients with cancer are being showcased at the ESMO Immuno-Oncology Congress,...
11 Dec 2018
Researchers predict that death rates from cancer will fall in 2018 in Australasian countries and in Russia. However, a greater proportion of the...
10 Dec 2018
It was also expected to be used in combination with bevacizumab to treat advanced or metastatic RCC
Geneva, Switzerland
13 Dec
- 16 Dec
2018
Lugano, Switzerland
01 Feb
- 02 Feb
2019
Capetown, South Africa
15 Feb
- 17 Feb
2019
Valencia, Spain
22 Feb
- 22 Feb
2019
Paris, France
25 Feb
- 27 Feb
2019
Manchester, United Kingdom
06 Mar
- 08 Mar
2019
